Osilodrostat treatment in patients with Cushing’s disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4)
Endocrine Journal · 2024 · 71 (12) · 1103-1123
DOI: 10.1507/endocrj.ej24-0153 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Endocrine Journal, 2024. Verfasst von Akira Shimatsu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Omi Medical Center, Kusatsu 525-8585, Japan. Hauptthemen laut MEDLINE: Pituitary ACTH Hypersecretion, Asian People. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Novartis Pharma AG.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Omi Medical Center, Kusatsu 525-8585, Japan.
- Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA 02114, USA.
- Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, OR 97239, USA.
- Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples 80131, Italy.
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, South Korea.
- Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
Förderung
- Novartis Pharma AG
Zitieren
APA
Shimatsu, A., Biller, B. M., Fleseriu, M., Pivonello, R., Lee, E. J., Leelawattana, R., Kim, J. H., Walia, R., Yu, Y., Liao, Z., Piacentini, A., Pedroncelli, A. M., & Snyder, P. J. (2024). Osilodrostat treatment in patients with Cushing’s disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4). Endocrine Journal, 71(12), 1103-1123. https://doi.org/10.1507/endocrj.ej24-0153
Vancouver
Shimatsu A, Biller BM, Fleseriu M, Pivonello R, Lee EJ, Leelawattana R, et al. Osilodrostat treatment in patients with Cushing’s disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4). Endocrine Journal. 2024;71(12):1103-1123. doi:10.1507/endocrj.ej24-0153
BibTeX
@article{Shimatsu2024,
author = {Shimatsu, Akira and Biller, Beverly Mk and Fleseriu, Maria and Pivonello, Rosario and Lee, Eun Jig and Leelawattana, Rattana and Kim, Jung Hee and Walia, Rama and Yu, Yerong and Liao, Zhihong and Piacentini, Andrea and Pedroncelli, Alberto M and Snyder, Peter J},
title = {Osilodrostat treatment in patients with Cushing’s disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4)},
journal = {Endocrine Journal},
year = {2024},
volume = {71},
number = {12},
pages = {1103--1123},
doi = {10.1507/endocrj.ej24-0153}
}
EUVIMED